Researchers at Washington University School of Medicine in St. Louis have pioneered a groundbreaking method utilizing a single blood draw to estimate the future onset of Alzheimer’s disease symptoms, potentially offering a multi-year heads-up before cognitive decline becomes apparent. This innovative approach, detailed in a February 19th publication in the esteemed journal Nature Medicine, demonstrates an impressive capacity to forecast symptom manifestation within a three-to-four-year timeframe. Such precision holds significant promise for accelerating the development of more efficient and precisely targeted clinical trials aimed at preventing Alzheimer’s, while also paving the way for the identification of individuals who stand to gain the most from early therapeutic interventions.
The societal burden of Alzheimer’s disease is substantial, with over seven million Americans currently diagnosed. Projections from the Alzheimer’s Association indicate that the financial strain of managing individuals with Alzheimer’s and other forms of dementia will approach a staggering $400 billion by 2025. Although a definitive cure remains elusive, the advent of tools capable of anticipating the emergence of symptoms could prove instrumental in efforts to delay or mitigate their impact.
Dr. Suzanne E. Schindler, an associate professor in the Department of Neurology at WashU Medicine and the study’s senior author, highlighted the transformative potential of this blood-based diagnostic. "Our work underscores the feasibility of employing blood tests, which are considerably more cost-effective and widely accessible than advanced brain imaging techniques or spinal fluid analyses, for the prediction of Alzheimer’s symptom onset," she stated. Dr. Schindler further elaborated that these predictive models could significantly shorten the evaluation period for potential preventive therapies.
"In the immediate future, these models will serve to expedite our research endeavors and clinical trials," Dr. Schindler remarked. "Ultimately, the aspiration is to equip individual patients with knowledge about their likely symptom development timeline, enabling them and their physicians to proactively devise strategies for prevention or symptom deceleration."
At the core of this predictive methodology lies the measurement of plasma p-tau217, a specific protein fragment found in the liquid component of blood. By meticulously analyzing the concentration of this biomarker, the research team was able to derive an estimated age at which an individual might commence experiencing Alzheimer’s-related symptoms. While current applications of p-tau217 testing are primarily focused on diagnosing Alzheimer’s in individuals already exhibiting cognitive impairment, its use in asymptomatic individuals outside of research settings is not yet recommended.
To meticulously ascertain the typical duration between an elevation in p-tau217 levels and the subsequent appearance of symptoms, Dr. Schindler, in collaboration with lead author Dr. Kellen K. Petersen, an instructor in neurology at WashU Medicine, delved into data collected from 603 independent-living older adults. These participants were enrolled in two long-standing research initiatives: the Knight Alzheimer Disease Research Center (Knight ADRC) at WashU Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a multi-institutional consortium spanning numerous research sites across the United States.
The investigation involved the assessment of plasma p-tau217 across various analytical platforms to ensure robustness and generalizability. Within the Knight ADRC cohort, p-tau217 levels were quantified using PrecivityAD2, a clinically available Alzheimer’s blood test developed by C2N Diagnostics. C2N Diagnostics is a spin-off enterprise from WashU, co-founded by distinguished WashU Medicine researchers Dr. David M. Holtzman and Dr. Randall J. Bateman, both of whom are also coauthors of the current study. For the ADNI participants, p-tau217 concentrations were measured using assays from different manufacturers, including one that has received clearance from the U.S. Food and Drug Administration.
Prior scientific investigations have established a strong correlation between elevated plasma p-tau217 levels and the accumulation of amyloid and tau proteins within the brain, as observable through PET scans. Amyloid and tau are aberrant proteins that progressively aggregate and are considered hallmark pathological features of Alzheimer’s disease. Their formation can commence many years prior to the manifestation of memory impairment.
Dr. Petersen drew an analogy to illustrate this principle: "Amyloid and tau levels are akin to tree rings – if we know the number of rings, we can ascertain the tree’s age. It turns out that amyloid and tau also accumulate in a predictable pattern, and the age at which their presence becomes detectable strongly predicts the timing of symptom onset in Alzheimer’s disease. We have discovered that this holds true for plasma p-tau217 as well, which serves as a proxy for both amyloid and tau accumulation."
The research team’s developed model demonstrated an ability to estimate the age of symptom onset with a margin of error approximating three to four years. Furthermore, the study revealed that an individual’s age influenced the pace at which symptoms emerged following an increase in p-tau217 levels. Older adults tended to develop symptoms more rapidly after the protein became elevated compared to their younger counterparts. This observation suggests that younger brains may possess a greater capacity to tolerate disease-related pathological changes for longer periods, whereas older individuals may exhibit symptoms at lower thresholds of underlying pathology.
For illustrative purposes, an individual whose p-tau217 levels began to rise at age 60 might experience symptom onset approximately two decades later. Conversely, if these elevated levels first appeared at age 80, symptoms would typically manifest around 11 years thereafter. The model’s consistent performance across multiple p-tau217 detection platforms further substantiates its reliability and broad applicability.
To foster continued scientific inquiry, the researchers have made their model development code publicly accessible. Dr. Petersen has also developed an intuitive web-based application designed to facilitate in-depth exploration of these predictive "clock" models by other researchers.
"These clock models possess the potential to enhance the efficiency of clinical trials by enabling the identification of individuals who are likely to develop symptoms within a defined temporal window," Dr. Petersen explained. "With ongoing refinement, these methodologies hold the promise of predicting symptom onset with sufficient accuracy for integration into routine clinical care."
He also noted that other blood biomarkers have been linked to cognitive decline in Alzheimer’s disease, and future studies incorporating a combination of these markers could further improve the precision of symptom onset predictions.
The scientific underpinnings of this breakthrough are rooted in the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium’s project titled "Biomarkers Consortium, Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease." This collaborative effort benefited from scientific and financial contributions from a diverse array of industry, academic, patient advocacy, and government partners, including AbbVie Inc., the Alzheimer’s Association®, the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation, Biogen, Janssen Research & Development, LLC, and Takeda Pharmaceutical Company Limited, with private sector funding managed by the FNIH.
The data utilized in the preparation of this report were sourced from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. While the investigators within ADNI contributed to the initiative’s design and data provision, they were not involved in the analysis or authorship of this specific publication. Statistical analyses were further supported by grant R01AG070941 from the National Institute on Aging.
About the Author
